Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

🎯 Johnson & Johnson (JNJ) 💰 Analysis Report 📅 Generated: 2026-06-11 17:46:41 ET

Investment Analysis: Johnson & Johnson (JNJ)

1. Investment Recommendation: HOLD

2. Target Price: $245.00 (3-month target price range: $235-$255)

3. Confidence Level: 0.75

4. Risk Score: 0.35 (Moderate-Low Risk)

5. Detailed Reasoning:

Fundamental Analysis Basis:

  • Fair Valuation: Current price of $238.33 falls within the calculated fair value range of $230-$250 from fundamental analysis
  • Strong Financials: Gross margins consistently 66-70%, ROE of 14.70%, manageable debt-to-asset ratio of 59.67%
  • Streamlined Business: Post-Kenvue spin-off creates pure-play, higher-margin Innovative Medicine & MedTech company
  • Pipeline Strength: Positive Phase 2/3 results for nipocalimab in rare blood disorder (wAIHA) with no FDA-approved treatments
  • Strategic Positioning: $1B investment in hard-to-treat cancers and rare disease focus enhances growth profile

Technical Analysis Basis:

  • Bullish Trend Structure: Price above all major moving averages (5-day: $235.75 > 60-day: $232.32)
  • Strong Momentum: MACD at 1.5581 with positive histogram of 1.4482 indicates accelerating upward momentum
  • Overbought Short-Term: RSI_6 at 76.58 and KDJ J-value at 102.22 suggest near-term consolidation likely
  • Key Levels: Immediate resistance at $239.50-$241.60, support cluster at $230-$232
  • Chip Distribution: 77.83% profit ratio with average cost at $231.77 supports price stability

Risk Considerations:

  • Talc Litigation Overhang: Recent $32M verdict reaffirms persistent liability, though manageable given $20B+ annual FCF
  • Patent Cliff: Stelara biosimilar competition represents known headwind
  • Technical Exhaustion: Short-term oscillators indicate high probability of pullback/consolidation
  • Valuation: Forward P/E of 20.43 reasonable but not deeply discounted

Market Sentiment & Context:

  • Positive Reassessment: Market shifting view from “sleepy legacy” to growth compounder
  • Defensive Attributes: Dividend aristocrat status provides downside support in volatile markets
  • Sector Tailwinds: Pharma/Biotech M&A boom (2026) benefits JNJ’s strong balance sheet
  • News Impact: Clinical success (nipocalimab) positive vs. talc verdict negative = net mildly positive

Investment Rationale:

The HOLD recommendation balances:

  1. Long-term Bullish Thesis: Streamlined structure, strong pipeline, financial strength
  2. Short-term Caution: Overbought technicals suggest waiting for better entry
  3. Fair Valuation: Current price near middle of fair value range ($230-$250)

Price Target Justification:

  • $245 Target: Based on fundamental fair value assessment, technical resistance breakout potential, and 12-month fundamental target
  • Expected Movement: ~2.8% upside from current $238.33 to $245.00
  • Time Horizon: 3-month primary target, with 6-month potential to $252
  • Downside Protection: Stop-loss at $229 (below key $230-$232 support)

Strategic Guidance:

  • Existing Holders: Maintain positions, consider adding on pullbacks to $230-$232
  • New Investors: Wait for pullback to $230-$232 support zone before initiating positions
  • Risk Management: Use stop-loss at $229 to protect against breakdown of bullish structure
  • Monitoring Points: Watch for daily close above $241.60 for breakout confirmation

Conclusion: Johnson & Johnson represents a high-quality healthcare compounder undergoing positive transformation. While short-term technicals suggest patience for better entry, the fundamental story supports maintaining exposure with a $245 price target reflecting fair value plus modest growth premium. ✅ Analysis Complete